title: [A patient with pancreatic cancer and multiple liver metastases after total pancreatectomy who showed a partial response to combination chemotherapy with gemcitabine and UFT].
abstract: A 69-year-old man underwent a complete pancreatectomy in March 2002 because of cancer of the body of the pancreas. Two months after surgery, the patient had multiple metastases to the liver, abdominal recurrence, and an elevated cancer antigen (CA) 19-9 level. Combination chemotherapy with gemcitabine and UFT was administered on an outpatient basis. Chemotherapy consisted of biweekly gemcitabine (1,000 mg/m(2)) and daily UFT (300 mg). After 3 months of treatment, a computed tomographic scan of the liver showed marked shrinkage of metastatic lesions, accompanied by a decrease in the CA19-9 level. The patient spent most of his time at home and worked as usual; his quality of life was maintained. The only adverse event was transient leukopenia (grade 2). He died of peritoneal dissemination in August 2003 (15 months after recurrence). Our experience suggests that combination chemotherapy with gemcitabine and UFT may promote tumor dormancy and relieve symptoms in patients with liver metastasis after surgery for pancreatic cancer or with recurrence of metastasis.
authors.affiliation: Dept. of Surgery, Seirei Hamamatsu General Hospital.
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Machida
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Ushida
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Suzuki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Toda
mesh_terms: D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018395:CA-19-9 Antigen / Q000097:blood; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D011788:Quality of Life; D012074:Remission Induction; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D018395:CA-19-9 Antigen; D004338:Drug Combinations; C096910:UFT(R) drug; D003841:Deoxycytidine; D005641:Tegafur; D014498:Uracil; D000093542:Gemcitabine